Key Drivers
- High liquidity
- Persistent cash burn
- Weak profitability
AIAI Summary
NRIX has shifted from a speculative platform play to a derisked, registrational‑stage commercialization bet—backed by a large cash runway (~$593M) and a Gilead partnership—making upcoming pivotal readouts the decisive value drivers (positive if interim/pivotal signals are favorable; catastrophic if they fail).
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •High liquidity
- •Persistent cash burn
- •Weak profitability
NRIX has a strong, low‑leverage balance sheet but sustained large operating losses, negative cash flow and poor returns that threaten capital sustainability.
Price Behavior
Key Price Behavior Insights:
- •Below average
- •Accelerating decline
- •Defined support
Short summary: The stock is in a short-term downtrend—closing $14.43 below the last month average (~$15.55), with accelerated weakness in mid‑March and nearby support around $14.4–$15.1 while resistance sits near $16.2–$16.3 (a sustained move back above ~$15.55 and through ~$16.2 would be constructive).
Mid‑March drop from about $15.04 to $14.43 accelerated weakness and raised near‑term downside risk
Sentiment & News
Key News Insights:
- •Large stake increase
- •Price down ~6%
- •Institutional conviction
Redmile bought ~4.42M Nurix shares (~$63.4M) this quarter, raising its position by ~$119.6M even as NRIX was down ~6% over the past year, signaling continued institutional conviction.
Redmile's sizable accumulation may help stabilize NRIX's share price and signal confidence that could attract other investors despite recent underperformance
Similar Companies in Healthcare
Other companies in the same sector with AI ratings